C R Bard Inc (BCR) Receives Average Rating of “Hold” from Analysts

C R Bard Inc (NYSE:BCR) has earned a consensus recommendation of “Hold” from the twelve brokerages that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $319.17.

BCR has been the subject of several analyst reports. Zacks Investment Research raised shares of C R Bard from a “hold” rating to a “buy” rating and set a $372.00 price target for the company in a research note on Tuesday, December 26th. ValuEngine cut shares of C R Bard from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Barclays increased their price target on shares of C R Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a research note on Monday, November 6th. Cowen reissued a “hold” rating and issued a $317.00 price target on shares of C R Bard in a research note on Friday, November 3rd. Finally, Needham & Company LLC reissued a “hold” rating on shares of C R Bard in a research note on Thursday, October 26th.

Shares of C R Bard (BCR) traded down $1.95 during midday trading on Tuesday, reaching $331.24. 4,714,800 shares of the company traded hands, compared to its average volume of 679,456. C R Bard has a one year low of $222.42 and a one year high of $337.73. The stock has a market cap of $24,140.00, a PE ratio of 43.64, a PEG ratio of 2.53 and a beta of 0.52. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.37 and a current ratio of 1.72.

C R Bard (NYSE:BCR) last posted its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share for the quarter, beating the consensus estimate of $2.96 by $0.06. C R Bard had a net margin of 9.51% and a return on equity of 19.39%. The business had revenue of $989.80 million during the quarter, compared to analysts’ expectations of $990.64 million. During the same quarter in the prior year, the company posted $2.64 EPS. The business’s revenue for the quarter was up 5.1% on a year-over-year basis. research analysts anticipate that C R Bard will post 11.89 earnings per share for the current fiscal year.

In related news, insider Christopher S. Holland sold 38,242 shares of the stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $334.04, for a total transaction of $12,774,357.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Betty D. Larson sold 5,906 shares of the stock in a transaction that occurred on Friday, October 20th. The stock was sold at an average price of $330.16, for a total transaction of $1,949,924.96. Following the transaction, the vice president now directly owns 10,753 shares of the company’s stock, valued at approximately $3,550,210.48. The disclosure for this sale can be found here. Insiders have sold a total of 129,681 shares of company stock valued at $43,125,017 in the last ninety days. 0.80% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in BCR. Stephens Inc. AR acquired a new stake in C R Bard during the 2nd quarter worth approximately $253,000. Choate Investment Advisors acquired a new stake in C R Bard during the 2nd quarter worth approximately $201,000. Profund Advisors LLC lifted its holdings in C R Bard by 7.9% during the 2nd quarter. Profund Advisors LLC now owns 3,146 shares of the medical instruments supplier’s stock worth $994,000 after buying an additional 231 shares in the last quarter. Citigroup Inc. lifted its holdings in C R Bard by 100.7% during the 2nd quarter. Citigroup Inc. now owns 114,620 shares of the medical instruments supplier’s stock worth $36,232,000 after buying an additional 57,501 shares in the last quarter. Finally, Public Sector Pension investment Board lifted its holdings in C R Bard by 176.3% during the 2nd quarter. Public Sector Pension investment Board now owns 45,133 shares of the medical instruments supplier’s stock worth $14,267,000 after buying an additional 28,800 shares in the last quarter. Institutional investors own 79.11% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “C R Bard Inc (BCR) Receives Average Rating of “Hold” from Analysts” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/16/c-r-bard-inc-bcr-receives-average-rating-of-hold-from-analysts-2.html.

C R Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Analyst Recommendations for C R Bard (NYSE:BCR)

Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply